Francesco Berti

USPTO Granted Patents = 30 (Patent Applications = 4)

CIPO Patents = 9 (Patent Applications = 3)

EPO Patents = 17 (Patent Applications = 29)

Average Co-Inventor Count = 2.6

ph-index = 4

Forward Citations = 52(Granted Patents)

Location History:

King of Prussia, PA (US) (2017)
Colle Val d'Elsa, IT (2013 - 2021)
Siena, IT (2013 - 2023)

Company Filing History:

23 out of 531

Glaxosmithkline Biologicals Sa

Novartis Vaccines and Diagnostics Srl

Years Active: 2013-2025

Loading Chart...

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12409231 - Cycloalkyne derivatized saccharides (2025-09-09),

2. 11612664 - Immunogenic compositions (2023-03-28),

3. 11208424 - type 5 capsular saccharides (2021-12-28),

4. 11135300 - Cycloalkyne derivatized saccharides (2021-10-05),

5. 11065323 - Purification method (2021-07-20),

6. 10736959 - Conjugation oftype 5 and type 8 capsular polysaccharides (2020-08-11),

7. 10668143 - Meningococcus serogroup X conjugate (2020-06-02),

8. 10245310 - Carrier molecule for antigens (2019-04-02),

9. 10188719 - [object Object] (2019-01-29),

10. 10172928 - Purification of streptococcal capsular polysaccharide (2019-01-08),

11. 10150979 - Purification of secreted polysaccharides from S. agalactiae (2018-12-11),

12. 10124051 - Meningococcus serogroup X conjugate (2018-11-13),

13. 9839686 - [object Object] (2017-12-12),

14. 9827301 - Hypo- and hyper-acetylated meningococcal capsular saccharides (2017-11-28),

15. 9803030 - Modified saccharides (2017-10-31),

Title: The Contributions of Francesco Berti: Innovator in Immunogenic Compositions

Introduction: Francesco Berti, based in Siena, Italy, is a remarkable inventor known for his contributions to the field of immunogenic compositions. With an impressive portfolio of 29 patents, Berti has made significant advancements in vaccine development and polysaccharide technology.

Latest Patents: Among Francesco Berti's latest patents is one that focuses on immunogenic compositions that include conjugates consisting of fragments of the capsular polysaccharide of Type III Group B Streptococcus (GBS). This invention outlines a method for producing suitable fragments through synthetic means or by depolymerization of native polysaccharide. Another noteworthy patent provides a method for releasing capsular polysaccharide from type 5 or type 8 cells, involving a treatment process using acid. The patent further details the purification of capsular polysaccharides from these cells, incorporating steps like enzymatic treatment, diafiltration, and anion exchange chromatography. These innovations underline Berti's commitment to enhancing vaccine efficacy and safety.

Career Highlights: Francesco Berti has built a distinguished career in pharmaceutical research, contributing his expertise in immunology and biochemistry at leading organizations. He has worked with prominent companies such as GlaxoSmithKline Biologicals and Novartis, where he has played critical roles in innovative research and development.

Collaborations: Throughout his career, Francesco Berti has collaborated with esteemed colleagues, including Paolo Costantino and Maria Rosaria Romano. These partnerships have not only enriched his professional experience but have also facilitated the advancement of significant medical technologies in the vaccine domain.

Conclusion: With his extensive portfolio of patents and impactful contributions to immunogenic composition technologies, Francesco Berti stands out as a pivotal figure in the field of biomedical innovation. His work continues to influence the development of effective vaccines, demonstrating the essential role of inventors in enhancing global health.

This text is generated by artificial intelligence and may not be accurate.